Zealand Pharma Refocuses Strategy

 

• Dr. Adam Steensberg assumes the position of Chief Executive Office refocusing Zealand to better leverage its next-generation peptide platform to address unmet medical needs of patients

• Commercial operations restructured to pursue partnerships for Zegalogue, V-Go and the glepaglutide and dasiglucagon late-stage clinical portfolio

• Annual operating expense reductions to be at least 35% from 2021 levels

• Conference call for investors and financial community will be held today at 4:30 PM CET/ 10:30 AM ET

The company will hold a conference call for investors and financial community at 4:30 PM CET/ 10:30 AM ET. Details can be found here: https://www.zealandpharma.com/events-cal and below.

Denmark, Copenhagen………....	+45 32 720 417
Denmark, tollfree……………….......	80 711 246
France, Paris……….........................	+33 (0) 170700781
Netherlands, Amsterdam.…..	+31 (0) 207956614
United Kingdom………………......	+44 (0) 844 481 9752
United States…………………….......	+1 646 741 3167
International……….......................	+44 (0) 2071 928338
Confirmation Code:……………...	7092317 https://finance.yahoo.com/news/zealand-pharma-appoints-chief-executive-131500198.html